Expert Opin Drug Metab Toxicol. 2022 Jan 7. doi: 10.1080/17425255.2021.2027367. Online ahead of print.
INTRODUCTION: Therapeutic drug monitoring (TDM) is useful for optimizing monoclonal antibodies (mAbs) for the treatment of immune-mediated inflammatory disorders including inflammatory bowel disease (IBD). However, TDM in clinical practice is still restricted by long turnaround times between sampling and results and the fact that dosing of mAbs to a target drug concentration is challenging due to high pharmacokinetic (PK) variability at both a population and patient level. Overcoming these barriers may be addressed by point-of-care (POC) assays, model-informed precision dosing (MIPD) and pharmacogenetics/pharmacogenomics.
AREAS COVERED: This review provides an overview of the optimization of TDM of mAbs in IBD including POC testing, MIPD and pharmacogenetics.
EXPERT OPINION: Recent advances in sampling, quantification, and support of clinical decisions include POC assays and PK dashboards which may allow for prompt and precise application of TDM in clinical practice. Future perspectives towards a more personalized implementation of TDM could include the incorporation of pharmacogenetics/pharmacogenomics to identify subgroups of patients who would benefit more from proactive TDM or combination therapy such as those prone to immunogenicity and/or accelerated drug clearance. However, there are still challenges regarding the implementation of these innovative approaches and more data from prospective studies and randomized controlled trials are needed.
View the full article